The Roles of MicroRNA in Lung Cancer

被引：227
作者：
Wu, Kuan-Li [1 ,2 ]
Tsai, Ying-Ming [1 ,3 ,4 ,5 ]
Lien, Chi-Tun [6 ]
Kuo, Po-Lin [7 ]
Hung, Jen-Yu [1 ,4 ,5 ,7 ]
机构：
[1] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Kaohsiung 807, Taiwan
[2] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Internal Med, Kaohsiung 807, Taiwan
[3] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan
[4] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Internal Med, Kaohsiung 807, Taiwan
[5] Kaohsiung Med Univ, Coll Med, Dept Resp Care, Kaohsiung 807, Taiwan
[6] Kaohsiung Municipal United Hosp, Dept Internal Med, Kaohsiung 804, Taiwan
[7] Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, Kaohsiung 807, Taiwan
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2019年 / 20卷 / 07期
关键词：
microRNA; lung cancer; EPITHELIAL-MESENCHYMAL TRANSITION; REGULATES CISPLATIN RESISTANCE; DOWN-REGULATION; CELL-PROLIFERATION; TUMOR-GROWTH; ACQUIRED-RESISTANCE; DEPENDENT MANNER; TARGETING KRAS; UP-REGULATION; NSCLC CELLS;
D O I：
10.3390/ijms20071611
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Lung cancer is the most devastating malignancy in the world. Beyond genetic research, epigenomic studies-especially investigations of microRNAs-have grown rapidly in quantity and quality in the past decade. This has enriched our understanding about basic cancer biology and lit up the opportunities for potential therapeutic development. In this review, we summarize the involvement of microRNAs in lung cancer carcinogenesis and behavior, by illustrating the relationship to each cancer hallmark capability, and in addition, we briefly describe the clinical applications of microRNAs in lung cancer diagnosis and prognosis. Finally, we discuss the potential therapeutic use of microRNAs in lung cancer.
引用
收藏
页数：25
相关论文
共 177 条
  • [1] Long-Term Cigarette Smoke Exposure and Changes in MiRNA Expression and Proteome in Non-Small-Cell Lung Cancer
    Advani, Jayshree
    Subbannayya, Yashwanth
    Patel, Krishna
    Khan, Aafaque Ahmad
    Patil, Arun H.
    Jain, Ankit P.
    Solanki, Hitendra S.
    Radhakrishnan, Aneesha
    Pinto, Sneha M.
    Sahasrabuddhe, Nandini A.
    Thomas, Joji K.
    Mathur, Premendu P.
    Nair, Bipin G.
    Chang, Xiaofei
    Prasad, T. S. Keshava
    Sidransky, David
    Gowda, Harsha
    Chatterjee, Aditi
    [J]. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2017, 21 (07) : 390 - 403
  • [2] Tumor suppressor miR-29c regulates radioresistance in lung cancer cells
    Arechaga-Ocampo, Elena
    Lopez-Camarillo, Cesar
    Villegas-Sepulveda, Nicolas
    Gonzalez-De la Rosa, Claudia H.
    Perez-Anorve, Isidro X.
    Roldan-Perez, Reynalda
    Flores-Perez, Ali
    Pena-Curiel, Omar
    Angeles-Zaragoza, Oscar
    Rangel Corona, Rosalva
    Gonzalez-Barrios, Juan A.
    Bonilla-Moreno, Raul
    del Moral-Hernandez, Oscar
    Herrera, Luis A.
    Garcia-Carranca, Alejandro
    [J]. TUMOR BIOLOGY, 2017, 39 (03)
  • [3] Cellular abnormalities of blood vessels as targets in cancer
    Baluk, P
    Hashizume, H
    McDonald, DM
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2005, 15 (01) : 102 - 111
  • [4] miR-15a and miR-16 Are Implicated in Cell Cycle Regulation in a Rb-Dependent Manner and Are Frequently Deleted or Down-regulated in Non-Small Cell Lung Cancer
    Bandi, Nora
    Zbinden, Samuel
    Gugger, Mathias
    Arnold, Marlene
    Kocher, Verena
    Hasan, Lara
    Kappeler, Andreas
    Brunner, Thomas
    Vassella, Erik
    [J]. CANCER RESEARCH, 2009, 69 (13) : 5553 - 5559
  • [5] MicroRNA expression differentiates between primary lung tumors and metastases to the lung
    Barshack, Iris
    Lithwick-Yanai, Gila
    Afek, Arnon
    Rosenblatt, Kinneret
    Tabibian-Keissar, Hila
    Zepeniuk, Merav
    Cohen, Lahav
    Dan, Harel
    Zion, Orit
    Strenov, Yulia
    Polak-Charcon, Sylvie
    Perelman, Marina
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2010, 206 (08) : 578 - 584
  • [6] Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors
    Beg, Muhammad S.
    Brenner, Andrew J.
    Sachdev, Jasgit
    Borad, Mitesh
    Kang, Yoon-Koo
    Stoudemire, Jay
    Smith, Susan
    Bader, Andreas G.
    Kim, Sinil
    Hong, David S.
    [J]. INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) : 180 - 188
  • [7] Overview upon miR-21 in lung cancer: focus on NSCLC
    Bica-Pop, Cecilia
    Cojocneanu-Petric, Roxana
    Magdo, Lorand
    Raduly, Lajos
    Gulei, Diana
    Berindan-Neagoe, Ioana
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2018, 75 (19) : 3539 - 3551
  • [8] Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients
    Bisagni, Alessandra
    Pagano, Maria
    Maramotti, Sally
    Zanelli, Francesca
    Bonacini, Martina
    Tagliavini, Elena
    Braglia, Luca
    Paci, Massimiliano
    Mozzarelli, Andrea
    Croci, Stefania
    [J]. PLOS ONE, 2018, 13 (04):
  • [9] Accurate Classification of Non-Small Cell Lung Carcinoma Using a Novel MicroRNA-Based Approach
    Bishop, Justin A.
    Benjamin, Hila
    Cholakh, Hila
    Chajut, Ayelet
    Clark, Douglas P.
    Westra, William H.
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (02) : 610 - 619
  • [10] Pathogenesis of lung cancer signalling pathways: roadmap for therapies
    Brambilla, E.
    Gazdar, A.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (06) : 1485 - 1497
12345678910